NAD+ Infusions, Supplements and Research Powders: Why Route and Formulation Matter

A clinic infusion, an oral precursor and a laboratory powder may share NAD+ terminology. Their molecules, formulations, intended uses and supporting evidence still require separate evaluation.

Imagine three products on the same search results page: an intravenous NAD+ infusion offered by a clinic, an oral nicotinamide riboside capsule, and a research-use powder sold to laboratories. A shopper could be forgiven for treating them as three prices for one thing. They are not. Each involves a different molecule or formulation, a different route into the body, a different rulebook, and a different body of evidence. Reading the route and formulation attached to a claim is the most useful habit for evaluating NAD+ marketing.

What the cited human infusion study measured

A 2019 pilot by Grant and colleagues, available in full text, examined intravenous NAD+ metabolism. Eleven healthy men aged 30 to 55, eight receiving NAD+ and three receiving saline, were studied during a six-hour intravenous infusion with the study preparation. Blood and urine were sampled through eight hours.^[1]

The results described changes in blood and urine chemistry. Plasma NAD+ did not rise during the first two hours and was substantially elevated at the end of the infusion. The paper discusses uptake and metabolism as explanations for the changing concentrations. Those observations characterize the handling of this preparation; they do not establish improved energy, memory or longevity.^[1]

No adverse events were observed during the six-hour infusion. That finding deserves to be retained, with its short observation window and small, selected population. The authors also identified unmeasured metabolic pathways that further research would need to examine. A study of eleven men cannot provide a general safety profile or show which route produces better clinical outcomes.^[1]

Oral precursors answer a different question

Compare the 2018 trial by Martens and colleagues: chronic oral supplementation with nicotinamide riboside (NR), a precursor vitamin the body uses to build NAD+, in a 2 × 6-week randomized, double-blind, placebo-controlled crossover study in healthy middle-aged and older adults. NR was well tolerated and effectively stimulated NAD+ metabolism, and the authors proposed future trials on blood pressure and arterial stiffness.^[2]

This is real human evidence, but it concerns a different molecule taken by a different route over weeks rather than hours. These two studies are not a head-to-head comparison of intravenous NAD+ against oral NR or NMN. They cannot establish that one route is clinically more effective than another. The infusion study tracks blood and urine chemistry over eight hours; the oral trial examines repeated precursor supplementation over six-week periods. Comparing the size of a change across these designs would mix treatment, timing and population differences.^[1]^[2]

Why “NAD+” on the label is not one product

NAD+, NADH, NMN and NR are distinct molecules with distinct behavior, a point explored in detail in our companion article on NAD+, NADH, NMN and NR chemistry. Even holding the molecule constant, formulation changes the question. An infusion solution requires controls relevant to sterile products, including microbial contamination and endotoxins, bacterial components associated with adverse reactions.^[3] An oral precursor reaches the body through a different route and enters NAD+ metabolism as a different molecule.^[2] A research powder’s chemical specification does not, by itself, document the controls needed for a sterile clinical product.

The infusion study illustrates why this matters scientifically: the body handles a molecule delivered straight into a vein, at a defined rate, in a way that cannot be assumed from swallowing a related compound. The shared name “NAD” cannot establish bioequivalence: evidence of comparable exposure cannot be inferred from similar labeling. Nor would a similar blood measurement alone establish the same clinical benefit. Our earlier feature on NAD+ infusions, biology and evidence follows the 2019 metabolome study in depth; here the point is what that study cannot say about other products.^[1]

The FDA endotoxin alert is about ingredients, not a verdict on NAD+

In 2024, FDA issued a reminder after becoming aware of compounders using food-grade NAD+ sold by repackagers to make intravenous products. The agency's point was specific: ingredients identified as food grade are not suitable for compounding sterile drugs without appropriate processing, because of the high risk of contamination with microbes and endotoxins.^[3]

FDA also reported receiving adverse event reports following use of NAD+ injectable drugs, including severe chills, shaking, vomiting and fatigue, some requiring medical treatment, and stated these reactions are consistent with excessive levels of endotoxins.^[3]

Two misreadings should both be resisted. The first converts the alert into “NAD+ infusions are inherently dangerous,” which the document does not say; FDA described reactions consistent with excessive endotoxins; the alert does not establish an intrinsic pharmacological cause or prove the cause of every individual reaction. The second treats “food grade” as a guarantee of suitability for any route. FDA specifically identified the gap between an ingredient intended for food and one suitable for sterile compounding.^[3]

Different intended uses carry different evidence

Dietary supplements occupy their own regulatory frame. FDA does not approve dietary supplements before they reach the market, and companies can often introduce a supplement without notifying the agency; FDA's role primarily begins after the product enters the marketplace, through facility inspections, label review and adverse-event monitoring. Products intended to treat, diagnose, cure or prevent disease are drugs under the law even when labeled as supplements.^[4]

“Not pre-approved” does not mean “no standards apply.” FDA states that supplement companies are responsible for meeting applicable safety standards and manufacturing and labeling requirements.^[4] These are United States regulatory distinctions; they do not establish a product’s legal status in every jurisdiction. Sterile compounded drugs sit in a different frame again, with ingredient-suitability expectations of the kind the 2024 alert describes. A laboratory reagent is a different intended-use context, and a purity percentage on a certificate answers only its defined analytical question. It does not establish sterility, endotoxin control, or suitability for human administration, and research materials should not be consumed or self-administered. This article establishes no clinical suitability for any Chudik Scientific research material.

Context	Evidence available	Missing inference
IV NAD+ pilot	Chemistry over hours	Lasting health benefit
Oral NR trial	NAD+ metabolism	Superiority to infusion
Research powder	Chemical specification	Human-use suitability

A practical way to read route claims

A proposed checklist when a NAD+ claim appears: identify the exact molecule, since NAD+, NMN, NR and NADH are not interchangeable; identify the route, because infusion and oral evidence cannot be swapped; identify the product class, since an approved-drug preparation, a supplement, a compounded sterile product and a research reagent carry different controls and different evidence; and ask what kind of finding is being cited, because a plasma concentration curve is not a health outcome.

A useful comparison keeps these evidence types separate. One small infusion study maps metabolism over hours; oral precursor trials show NAD+ metabolism can be stimulated over weeks; a federal alert shows what can go wrong when a food-grade ingredient is asked to do a sterile product's job. Neither study establishes a clinical efficacy ranking between routes. A product comparison that omits the actual preparation and endpoint leaves out the information needed to judge its claim.

Selected methods, results, discussion and disclosure sections of the infusion paper’s supplied full text were reviewed; the NR trial is represented by its original published abstract, and the FDA documents are public web pages. Trial-level details available only in the NR paper's full text are beyond this article's scope.